Skip to main content
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in:

Open Access 12-04-2025 | IgA Nephropathy | Commentary

An Expert Opinion on Current and Future Treatment Approaches in IgA Nephropathy

Author: Richard J. Glassock

Published in: Advances in Therapy | Issue 6/2025

Login to get access

Excerpt

Since multiple novel treatments for immunoglobulin A nephropathy (IgAN) have become available in recent years, with many more in development, the 2021 Kidney Disease: Improving Global Outcomes clinical practice guidelines are of limited relevance in modern practice
These novel agents specifically target the underlying disease pathophysiology of IgAN for improved efficacy and safety, but their place in the IgAN treatment approach has not been established
To address the need for updated guidance, this article proposes a novel approach to IgAN treatment based on the author’s clinical expertise and interpretation of the available literature, which incorporates the established, recently approved, and late-phase-development pipeline agents
Although this approach may serve as a general guide for clinicians, it is most important to consider the clinical and pathologic characteristics of individual patients when making treatment decisions in IgAN
…
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
An Expert Opinion on Current and Future Treatment Approaches in IgA Nephropathy
Author
Richard J. Glassock
Publication date
12-04-2025
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 6/2025
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-025-03187-7

Other articles of this Issue 6/2025

Cost-Effectiveness Analysis of SGLT2 Inhibitors for Cardio-Renal-Metabolic Disease Based on Data from Japanese Studies

LDL-C Reduction with Evolocumab Among Patients with ASCVD in China: Real-World Evidence from Tianjin Metropolitan Area

The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity

Improving Clinical Management and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis in China via Real-world Evidence (IMPROVE Study): A Multicenter Prospective Cohort Study

A Cost-Effectiveness Analysis of Abemaciclib in Combination with Adjuvant Endocrine Therapy for HR+, HER2–, Node-Positive, High-Risk Early Breast Cancer

Co-treatment with Gabapentinoid and Japanese Herbal Medicine Goshajinkigan for CIPN is Associated with Longer Duration and Higher Dose of Chemotherapy

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s 85th Scientific Sessions.

Read more
Image Credits